Quebec City, Quebec, January 23, 2018 – Opsens Inc. (“Opsens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF) today held its annual general shareholders’ meeting (the “Meeting”) at its head office in Quebec City, Canada.
Opsens’ shareholders re-elected Denis M. Sirois, Denis Harrington, Pat Mackin, Jean Lavigueur, Gaétan Duplain and Louis Laflamme as members of the Board of Directors of the Corporation.
Claude Belleville Announces His Retirement From Opsens
After co-founding and evolving with Opsens for the past 14 years, Mr. Belleville is retiring as Vice President, Medical Devices. To ease the transition, Mr. Belleville will continue as a consultant for the Company. His duties will be reassigned to several people within the Company.
“We thank Claude for his immense contribution to Opsens. With his vision, energy and determination, he played a major role in the growth of the Company. He has developed, with his strong and capable team, the best FFR guidewire on the market to ensure a bright outlook for Opsens,” said Louis Laflamme, Opsens’ President and CEO.
“I am leaving Opsens with a sentiment of accomplishment. I enjoyed positioning Opsens as an innovative cardiology company in the FFR market, and I had the chance to lead a great team, which will continue to push our innovation forward and enhance our technological edge. Opsens is now a strong Company as shown by its record quarterly revenues for the first quarter of 2018. I believe it is time for me to move on to new challenges. I am very confident with the team we have put in place and I believe that Opsens can continue its progression in the growing FFR market for many years to come,” added Mr. Belleville.
“On behalf of the Board of Directors, we would like to thank Claude for his performance throughout his remarkable career with Opsens. We wish him the best in his future endeavors,” said Denis M. Sirois, Chairman of the Board.
About Opsens Inc. (www.opsens.com or www.opsensmedical.com)
Opsens focuses mainly on the measure of FFR in interventional cardiology. Opsens offers an advanced optical-based pressure guidewire (OptoWire) that aims at improving the clinical outcome of patients with coronary artery disease. Opsens is also involved in industrial activities in developing, manufacturing and installing innovative fibre optic sensing solutions for critical applications.
Forward-looking statements contained in this press release involve known and unknown risks, uncertainties and other factors that may cause actual results, performance and achievements of Opsens to be materially different from any future results, performance or achievements expressed or implied by the said forward-looking statements.
Neither TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX) accepts responsibility for the adequacy or accuracy of this release.
For further information, please contact:
Louis Laflamme, CPA, CA, Chief Executive Officer, 418.781.0333
Robin Villeneuve, CPA, CA Chief Financial Officer, 418.781.0333